Please assess the completion status of the following clinical trial:

Trial Title: Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects ages 18 to 70 years~* HCV-Infected Genotype 1 Null responders to current standard of care~* Expansion Cohorts A1 and A2 are restricted to patients infected with HCV Genotype 1b only.~Exclusion Criteria:~* Evidence of a medical condition associate with chronic liver disease other than HCV~* History of variceal bleeding, hepatic encephalopathy, or ascites requiring management with diuretics or paracentesis~* History of Cancer within 5 years of enrollment~* History of gastrointestinal disease or surgical procedure (except Cholecystectomy)~* History of clinically significant cardiac disease~* History of Glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Documented cirrhosis within 12 months prior to dosing~* Positive for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Sentinel A (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (600 mg) twice daily
- Arm 2: Sentinel B (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (600mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
- Arm 3: Expansion A1 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200mg) twice daily
- Arm 4: Expansion A2 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200mg) once daily
- Arm 5: Expansion B1 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200 mg) twice daily + Pegylated-interferon alfa-2a + Ribavirin
- Arm 6: Expansion B2 (Type: EXPERIMENTAL): BMS-790052 (60mg) once daily + BMS-650032 (200 mg) once daily + Pegylated-interferon alfa-2a + Ribavirin
- Arm 7: Expansion B3 (Type: EXPERIMENTAL): BMS-790052 (60 mg) once daily + BMS-650032 (200 mg) twice daily + Ribavirin

Based on this trial design, predict the completion outcome and termination type (if applicable).